ImCheck Therapeutics develops a new generation of immunotherapeutic antibodies targeting butyrophilins. Its lead clinical-stage program, ICT01, is a pathogen-agnostic γ9δ2 T cell-activating monoclonal antibody currently in a Phase I/IIa clinical trial across solid tumors and hematologic malignancies. The company is also advancing ICT41 toward clinical development as an infectious disease candidate. ImCheck's approach includes activating antibodies designed to modulate innate and adaptive immunity and antagonist antibodies being evaluated for autoimmune and infectious-disease indications. The company benefits from scientific support from Prof. Daniel Olive and an experienced management team, and has backing from a broad syndicate of leading US and European life-science investors. ImCheck is based in Marseille and has been recognized in the French Tech 120 and French Tech 2030 programs. ImCheck Therapeutics designs and develops a new generation of antibodies targeting the butyrophilin (BTN) superfamily to modulate innate and adaptive immunity. Its lead clinical candidate, ICT01, is a first-in-human anti-BTN3A antibody that activates γδ T cells and is being evaluated in combination with PD-1 inhibitors across multiple solid tumors and hematologic cancers. The company’s pipeline includes both activating antibodies for cancer and infectious diseases and antagonist antibodies for autoimmune indications. The EUR 96 million financing will support completion of randomized Phase II trials, Phase IIa expansion arms of the EVICTION study, and an upcoming EVICTION-2 trial exploring combinations including IL-2. ImCheck plans to advance additional antibody candidates toward the clinic and achieve pivotal study readiness for ICT01 while expanding clinical operations and regulatory affairs in Europe and the US. Headquartered in Marseille, France, the company has secured funding to extend its cash runway through 2026. ImCheck Therapeutics develops a new generation of immunotherapy antibodies targeting the butyrophilin superfamily and activating γ9δ2 T cells. Its lead program is ICT01, a first-in-class γ9δ2 T cell‑activating monoclonal antibody (anti-butyrophilin 3A) in the EVICTION Phase I/IIa clinical trial (NCT04243499). The company also maintains a preclinical portfolio of activating and antagonist antibodies aimed at immuno-oncology, autoimmune and infectious disease indications. ImCheck positions its agents to modulate both innate and adaptive immunity and to be used alone or in combination to overcome resistance to first‑generation immune checkpoint inhibitors. It has secured a total of €54 million in Series B capital to support the EVICTION trial and accelerate preclinical development. The company benefits from scientific support from Prof. Daniel Olive and an experienced management team. ImCheck Therapeutics is a Marseille, France–based biotech led by CEO Pierre d’Epenoux focused on first-in-class antibodies to activate gamma delta (gd) T cells and a portfolio of novel immunotherapies. Its core programs include the monoclonal antibody ICT01 and a broad pipeline of immunomodulators targeting the butyrophilins super-family. The company plans to use the Series B proceeds to fund the initial clinical trial for ICT01 and to advance additional immuno-oncology antibody programs into the clinic. ImCheck also aims to further expand its pipeline of immunomodulators for cancer and autoimmune indications. The company benefits from scientific support from Prof. Daniel Olive, a leader in gd T cells and butyrophilins research. The Series B financing strengthens ImCheck’s balance sheet to execute its near-term clinical and development plans. ImCheck Therapeutics is developing a new generation of proprietary immuno-modulatory antibodies that act on both adaptive and innate immunity, with a particular focus on gamma-delta T cells. The company has developed two first-in-class immunomodulator antibodies and is advancing several discovery programs on undisclosed targets that play defined immune-modulating roles. Founded in 2015 as a spin-off from Institut Paoli-Calmettes around Professor Daniel Olive, ImCheck is based in Marseille, France. The company is led by newly appointed CEO Pierre d’Epenoux, who brings two decades of operational management and corporate development experience in pharma and biotech. ImCheck intends to use recent financing to advance multiple drug candidates and to achieve entry into the clinic by 2019. The financing strengthens the company’s ability to progress its discovery programs toward clinical development.

Total raised

$205M

Funding rounds

5

Latest round

Series C

Latest activity

Jun 2022